STAT

Opinion: Drug sensitivity and resistance testing could make ‘right to try’ a real thing

There's no catalog of available drugs that can help patients pursuing #RightToTry options. An updated technique once developed for cancer might match patients with experimental drugs.

The contentious “right to try” bill that President Trump signed into law to help terminally ill patients get access to treatments that might — I emphasize the “might” — cure them or prolong their lives is more wishful thinking than it is reality.

Right to try implies that a catalog of available drugs exists that can help patients if only they could get access to them. It’s easy to believe in a shelf of miracle cures to stop cancer — after all, media outlets are full of anecdotal stories of cancer patients who are now disease free.. But those cases are rare.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks